source
- Pharma pours billions into bispecifics, ADCs and cell therapies despite limited clinical proofThe article notes that emerging drug formats such as bispecific antibodies, antibody‑drug conjugates and cell therapies have yet to demonstrate clear clinical success, yet pharmaceutical firms cont…
- Roche signs $15 billion ADC partnership with China's Hansoh, offering $400 million upfrontRoche announced a licensing agreement with Hansoh Pharmaceutical to develop a broad portfolio of antibody-drug conjugates (ADCs).\n\nThe deal includes an upfront cash payment of $400 million and a…